Overexpression of G_sα compensates for myocyte loss in diabetic cardiomyopathy

Author： Malhotra Ashwani Kang Barinder P.S. Vashistha Himanshu Yadav Virender S. Meggs Leonard G.

ISSN： 1205-7541

Source： Canadian Journal of Physiology and Pharmacology, Vol.86, Iss.3, 2008-03, pp. : 122-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mangiferin mitigates diabetic cardiomyopathy in streptozotocin-diabetic rats

By Zheng Dezhi Zhong Guocheng Hu Yonghe

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 9, 2013-01 ,pp. : 759-763

NRC Research Press

Access to resources Recommend Favorite

Oxidative stress: a key contributor to diabetic cardiomyopathy

By Khullar Madhu Al-Shudiefat Abd Al-Rahman S. Ludke Ana Binepal Gursonika Singal Pawan K.

Canadian Journal of Physiology and Pharmacology, Vol. 88, Iss. 3, 2010-03 ,pp. : 233-240

NRC Research Press

Access to resources Recommend Favorite

Medicinal Chemistry of Drugs Used in Diabetic Cardiomyopathy

Current Medicinal Chemistry, Vol. 17, Iss. 6, 2010-02 ,pp. : 517-551

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy

Current Pharmaceutical Design, Vol. 17, Iss. 30, 2011-10 ,pp. : 3341-3347

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 12, Iss. 2, 2012-06 ,pp. : 132-147

Bentham Science Publishers

Access to resources Recommend Favorite